Nabriva Therapeutics plc
NBRVF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $36 | $27 | $5 | $8 |
| % Growth | 31.1% | 441.4% | -35.1% | – |
| Cost of Goods Sold | $29 | $13 | $2 | $0 |
| Gross Profit | $7 | $14 | $3 | $8 |
| % Margin | 19.9% | 51.7% | 68.5% | 99.1% |
| R&D Expenses | $14 | $13 | $15 | $26 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $45 | $52 | $55 | $62 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | -$2 | -$1 | -$2 |
| Operating Expenses | $63 | $63 | $70 | $87 |
| Operating Income | -$55 | -$49 | -$66 | -$79 |
| % Margin | -155.6% | -178.3% | -1,315.4% | -1,025.9% |
| Other Income/Exp. Net | -$0 | -$0 | -$3 | -$3 |
| Pre-Tax Income | -$56 | -$49 | -$69 | -$83 |
| Tax Expense | $2 | $0 | $0 | $0 |
| Net Income | -$57 | -$49 | -$69 | -$83 |
| % Margin | -160.3% | -181.7% | -1,382.2% | -1,068.2% |
| EPS | -21.32 | -28.52 | -135.23 | -278.75 |
| % Growth | 25.2% | 78.9% | 51.5% | – |
| EPS Diluted | -21.32 | -28.52 | -135.23 | -278.75 |
| Weighted Avg Shares Out | 3 | 2 | 1 | 0 |
| Weighted Avg Shares Out Dil | 3 | 2 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $2 | $4 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$55 | -$47 | -$67 | -$79 |
| % Margin | -153.4% | -174.2% | -1,330.3% | -1,016% |